American College of Rheumatology/ EULAR Remission Criteria for Rheumatoid Arthritis: 2022 Revision

Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial

(2021) René Westhovens et al.   ANNALS OF THE RHEUMATIC DISEASES

Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial

(2021) Bernard Combe et al.   ANNALS OF THE RHEUMATIC DISEASES

2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis

(2021) Elena Nikiphorou et al.   ANNALS OF THE RHEUMATIC DISEASES

Definition of Treatment Targets in Rheumatoid Arthritis: Is It Time for Reappraisal?

(2021) Ricardo J.O. Ferreira et al.   JOURNAL OF RHEUMATOLOGY

2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

(2021) Liana Fraenkel et al.   Arthritis & Rheumatology

Back to Basics: Prioritizing Communication as a Key Instrument in Managing Rheumatoid Arthritis

(2021) Paul Studenic et al.   JOURNAL OF RHEUMATOLOGY

Considerations and priorities for incorporating the patient perspective on remission in rheumatoid arthritis: An OMERACT 2020 special interest group report

(2021) Bethan Jones et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update

(2020) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Testing different thresholds for patient global assessment in defining remission for rheumatoid arthritis: are the current ACR/EULAR Boolean criteria optimal?

(2020) Paul Studenic et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate‐naïve Patients with Moderately to Severely Active Rheumatoid Arthritis (SELECT‐EARLY): A Randomized, Double‐blind, Active‐comparator, Multi‐center, Multi‐country Trial

(2020) Ronald van Vollenhoven et al.   Arthritis & Rheumatology

Revisiting the use of remission criteria for rheumatoid arthritis by excluding patient global assessment: an individual meta-analysis of 5792 patients

(2020) Ricardo J O Ferreira et al.   ANNALS OF THE RHEUMATIC DISEASES

Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis

(2020) Andrea Rubbert-Roth et al.   NEW ENGLAND JOURNAL OF MEDICINE

Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study

(2019) Josef S Smolen et al.   LANCET

Do Patients with Moderate or High Disease Activity Escalate RA Therapy According to Treat‐to‐Target Principles? Results from the ACR's RISE Registry

(2019) Huifeng Yun et al.   ARTHRITIS CARE & RESEARCH

OUP accepted manuscript

(2018)   RHEUMATOLOGY

Suppressing Inflammation in Rheumatoid Arthritis: Does Patient Global Assessment Blur the Target? A Practice-Based Call for a Paradigm Change

(2018) Ricardo J. O. Ferreira et al.   ARTHRITIS CARE & RESEARCH

Comparative Assessment of the Different American College of Rheumatology/European League Against Rheumatism Remission Definitions for Rheumatoid Arthritis for Their Use as Clinical Trial End Points

(2017) Michael E. Mack et al.   Arthritis & Rheumatology

Different Rating of Global Rheumatoid Arthritis Disease Activity in Rheumatoid Arthritis Patients With Multiple Morbidities

(2017) Helga Radner et al.   Arthritis & Rheumatology

Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force

(2015) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

(2015) Jasvinder A. Singh et al.   ARTHRITIS CARE & RESEARCH

Tocilizumab Inhibits Structural Joint Damage and Improves Physical Function in Patients with Rheumatoid Arthritis and Inadequate Responses to Methotrexate: LITHE Study 2-year Results

(2013) R. M. FLEISCHMANN et al.   JOURNAL OF RHEUMATOLOGY

Near misses of ACR/EULAR criteria for remission: effects of patient global assessment in Boolean and index-based definitions

(2012) Paul Studenic et al.   ANNALS OF THE RHEUMATIC DISEASES

Discrepancies between patients and physicians in their perceptions of rheumatoid arthritis disease activity

(2012) Paul Studenic et al.   ARTHRITIS AND RHEUMATISM

Validity and Reliability Problems with Patient Global as a Component of the ACR/EULAR Remission Criteria as Used in Clinical Practice

(2012) K. R. MASRI et al.   JOURNAL OF RHEUMATOLOGY

Physical disability in rheumatoid arthritis is associated with cartilage damage rather than bone destruction

(2011) D. Aletaha et al.   ANNALS OF THE RHEUMATIC DISEASES

American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials

(2011) David T. Felson et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE))

(2010) P. Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

Treating rheumatoid arthritis to target: recommendations of an international task force

(2010) J. S. Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

(2009) Josef S Smolen et al.   LANCET